INTRODUCTION
tation products currently approved by the FDA, both temporary fillers and permanent fillers adhere perfectly to these qualities, and complications range from minor (bruising) to severe (embolisms, blindness). 7, 8 As a result, it was not long before autologous fat transfer (AFT) or lipofilling found its way as a potentially superior facial filler with numerous studies reporting on the promising results besides minimal side effects. [9] [10] [11] Numerous reviews and articles describing the authors preferred method for facial AFT currently exist, [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] but they generally lack a comprehensive study design. Furthermore, the abundance of anatomical facial zones further complicates pooling of data, with most authors describing its appliance to 1 or 2 facial regions. 10 Therefore, the aim of this systematic review was to determine the rejuvenating properties of AFT to the whole face in terms of volume enhancement and patient/surgeon satisfaction and objectify these terms by determining technique, complications, volume retention, and specific patient/surgeon satisfaction rates.
METHODS
A systematic review of literature reporting on technique, efficacy, and patient/surgeon satisfaction rates regarding AFT for facial rejuvenation was conducted according to the preferred-reporting-items-for-systematicreviews-and-meta-analysis (PRISMA) statement. 27 Medline (Ovid), Embase.com, and Cochrane Library (Wiley) were searched from inception (by JG and TK) up to December 11, 2016 . The following terms were used (including synonyms and closely related words) as index terms or free-text words: "facial" and "rejuvenation" or "aging" or "wrinkles" and "Autologous-Fat-Transfer." The full search strategies can be found in the supplementary information (see Appendix, Supplemental Digital Content 1, which displays the search strategy for Pubmed, http://links.lww. com/PRSGO/A628). Studies that were considered relevant based on the titles were stored using Endnote (Clarivate Analytics), 28 with no restriction on language, study design, or publication media. Bibliographies of relevant articles were manually searched for relevant or missed references.
Eligibility Criteria
Original randomized controlled trials (RCTs) and cohort studies on facial rejuvenation with the use of AFT with or without supplementation, which reported on efficacy (ie, volume enhancement, improving skin trophicity, and decreasing wrinkles), technique, and patient/surgeon satisfaction, were included. Studies reporting on AFT for facial rejuvenation in conjunction with/or following other surgical procedures or injectables were excluded. However, studies combining AFT with laser-resurfacing techniques or studies that included combinations of treatment (ie, AFT + surgical procedures) but clearly reported on AFT-specific complications were included. Duplicate articles, case reports, or case series with a sample size <10 and articles with a mean follow-up period <6 months were excluded. 
Study Selection
Articles were screened for relevancy by 2 independent reviewers (JG, TK). When considered eligible by both reviewers, the full-text article was retrieved for possible inclusion. Discrepancies between the 2 reviewers were discussed and when a solution was not found, a third reviewer (JH) was consulted. When a study could not be retrieved, the authors were contacted to request a copy of the original article.
Outcome Measures
We included the following outcomes: 1. facial rejuvenating properties (ie, volume enhancement, improving skin trophicity, decreasing wrinkles) objectified in numerical (ie, percentile) or ordinal scale 2. complications 3. patient/surgeon satisfaction.
Data Extraction
Data were extracted by 1 researcher (JG) using standardized tables developed for this purpose and checked by a second reviewer (TK). Extracted data included the following: country, publication year, study design, number of subjects, AFT technique, complication rate and management, volumetric measurements, and satisfaction rates. Included studies were evaluated with respect to the following factors: inclusion/exclusion criteria, patient selection (ie, consecutive versus nonconsecutive recruitment), and use of objective outcomes. Included studies were assigned a level of evidence (OCEBM, 2011) by 2 independent reviewers (JG, TK). The principal summary measures are rates or actual numbers with percentages given between parentheses, besides means over follow-up periods.
Assessment of Risk of Bias
Observational studies and clinical trials without detailed randomization protocols were considered studies with high risk of bias. The Cochrane Risk of Bias for Randomized Clinical Trials 29 and Risk-Of-Bias-In-Non-randomized-Studies-of-Interventions (ROBINS-I) 30 were used for quantifying the risk of bias across RCTs and non-RCTs respectively.
Data Synthesis
In accordance with the Cochrane Handbook for Metaanalyses, in the studies that compared 2 methods, only the data from the group treated with AFT was used.
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Statistical Analysis
R statistical software was used for analyzing the data. 32 The pooled proportion of complications was estimated by both a fixed and random-effects model. The amount of heterogeneity between the studies was tested with Cochrane's Q and quantified with I 2 . A random-effects model was used if Q was significant, a fixed effects model otherwise.
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RESULTS
There was a high interrater agreement, in selecting relevant articles based on the abstract screening, of 0.88. After screening (Fig. 1) , a total of 18-English writtenarticles were included. The risk of bias across the cohort studies (Table 1) was considered moderate in 80%. The risk of bias of the 3 comparative studies is illustrated in Figure 2 . Extracted data are summarized in Tables 1-5 . The included studies were published between 1990 and 2016, with 13 retrospective and 2 prospective cohort designs next to 3 trials. There were 17 level-III studies and 1 level-II study involving a total of 3,073 patients. Two studies 35, 36 studied the same set of patients by applying different methods of preparation or supplementation respectively using 2 different sides of the face (split over a vertical axis). The mean follow-up period was 13.9 months (range: 9-133).
Fat Grafting Technique
All articles described, to some extent, the methods of preparing and grafting the adipose tissue (Table 2) . 9, 35, 36, [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] Eleven out of 14 studies used a local form of anesthesia, 9,36,38-42,44-46,48,49,51,52 and 3 authors preferred general anesthesia. 35, 47, 50 The abdomen was the primary donor site in most studies with fat from the thigh and flank area used in cases of insufficient supply. The infiltration cannula size was poorly reported, with 3 studies 35, 40, 46 reporting using 1-, 2-, or 3-mm cannulas, respectively, and the infiltration solution varied widely among studies. Ten studies 9, 35, 40, 41, [45] [46] [47] [48] [49] [50] (additionally) used some form of local anesthetic in combination with different solutions of epinephrine and saline before harvesting by way of manual aspiration in 16 of Addition of supplementation, the number of sessions, and the injected volume are subsequently given. *Sedimentation (the process of settling down of heavy solids in a mixture of a liquid and insoluble solid) and decantation (the removal of the clear layer of the liquid without disturbing the settled solids) are used interchangeably because it both describes the process of letting the lipoaspirate settle to remove the desired layer. In the table, decantation is used. †Manual aspiration was used when the desired volume of fat was <10 ml, and a liposuction device was used when this exceeded 10 ml. AFT, autologous fat transfer; BLI, blunt lamis infiltrator; CC, Coleman cannula; CS, Coleman's solution; DFA, dermo-fascial attachment; FF, freezing of fat; h, number of cannula holes; LD, liposuction device; LLS, Luer lock syringe; LO, lateral opening; LRS, lactate Ringer solution; MA, manual aspiration; n, sample size; NaBic, sodium bicarbonate; NaCl, sodium chloride; NLF, nasolabial fold; NR, not reported; NS, not specified; PRF, platelet-rich fibrin; PRP, platelet-rich plasma; SMAS, superficial muscular aponeurotic system; SVF, stromal vascular fraction. 48 and Botti et al. 35 comparing centrifugation and washing between groups. Furthermore, 6 studies 38-41,43,51 used combinations of preparations in a none-comparative study design. Stromal vascular fraction (SVF), platelet-rich fibrin (PRF), and platelet-rich plasma (PRP) were used to supplement the fat in 4 studies, 2 by comparative design. 36, 45 The injection cannula sizes ranged from 1 to 3 mm (14-23 gauge) and were mostly blunt with 2 studies reporting using lateral openings 35, 48 and 1 study using a ratchet gun for precise fat distribution. 46 For the injections, most studies described a retrograde injection technique. The primary site of injection was the subcutaneous space with additional injections most often performed above or just beneath the superficial muscular aponeurotic system (SMAS). 52 recommending massage, as opposed to other studies. 53 -in the case of between-trial heterogeneity-the random-effects meta-analysis weights the studies relatively more equally and is therefore used in the following description. The overall complication rate was 6% (95% CI: 3.0-14.0) after a mean follow-up of 15.8 months in 1,205 patients (see Tables, Supplemental Digital Content 2, which displays different data charts including overall complications and infections, http://links. lww.com/PRSGO/A629). Hematoma/ecchymosis most reported (5%, 95% CI: 2.0-15.0), followed by fat necrosis/ oil cysts (2%, 95% CI: 1.0-5.0), irregular fat distribution and scars (both 2%, 95% CI: 1.0-4.0). Infections were reported in 1% (95% CI: 0.0-4.0) of 728 patients in 6 studies.
Preparation
Supplementation
Volume Retention
Objective measurements of the volumetric result are imperative to demonstrate the efficacy of AFT. However, the face consists of multiple anatomical units greatly varying in important features like density causing great heterogeneity in comparing results. Five studies 36, 38, 40, 45, 51 were included in the volumetric analysis (Table 4 ). The methods of determining volume retention varied greatly between studies. Supplements added to the fat graft were reported in 3 studies. As great heterogeneity between studies in regard to injection site and volumetric assessment exists, no pooling of data could be achieved, and volume retention varied greatly from 13% to 68% over a mean of 12.2 months.
Patient/Surgeon Satisfaction
A total of 9 studies 9, 35, 36, 39, 41, 44, 46, 48, 52 reported on patient and/or surgeon satisfaction either on a visual analog scale (VAS) or a 2-4 point Likert scale (Table 5) . Meta-analysis for patient satisfaction was performed after conversion to a dichotomous scale (see Tables, Supplemental Digi .4%]), the random-effect model was used for reporting patient satisfaction. Furthermore, overall scores were used only postoperatively, and when satisfaction rates were compared between study groups, 48 a mean over the total cohort was calculated. The satisfaction rate over a total cohort of 630 patients in 6 studies 36, 41, 44, 46, 48, 52 was 81% (95% CI: 70.0-89.0). It should be noted that Asilian et al. 48 compared 2 groups of patients according to preparation method (centrifugation vs filtering/washing), and both groups were included in the analysis. Surgeons reported a good cosmetic outcome in 89%, and the overall postoperative mean VAS score among 88 patients in 2 reporting studies 9,35 was 79.5.
DISCUSSION
This study was performed to obtain a comprehensive overview of the available evidence on the outcomes of AFT in facial rejuvenation with objective outcome measures and a clear description of the technique applied. The first remarkable issue is the small number of studies to evaluate AFT in rejuvenation of the face. Although AFT is used widely all over the world, the number of well-designed studies is limited.
As is the case in AFT for other indications-such as the breast-the techniques used for harvesting, preparation, and reinjection of the fat varied greatly among authors. The most important aim in this continuing search for the golden standard in AFT is improving the volume retention, which is believed to be influenced by almost all the AFT aspects. Whether shear stress of the adipocytes caused by cannula size (either during harvesting or injection) or high osmolality of the infiltration solution plays a role remains a matter of debate. Both have been shown to vary greatly in this systematic review but have also been shown to matter significantly to the long-term volume retention. 54 Two recently published in vitro studies 55, 56 shed some light on this interesting topic with Hivernaud et al. 56 reporting on-among others-adipose tissue resorption variances between different combinations of harvesting (ie, manual, power-assisted, or water-assisted lipoaspiration) and preparation (ie, decantation, centrifugation, or filtration). They found that both in the in vitro and in the murine models, greater efficiency (in terms of retaining tissue volume) was achieved with manual aspiration, soft centrifugation (400 g for 1 min), and washing steps. Although the majority of studies in this systematic review used manual aspiration, the centrifugation settings and times were considerably higher. Secondly, Streit et al. 55 further studied the differences in morphology between fat samples obtained through decantation, centrifugation, and membrane-based tissue filtration and found the highest numbers of adipose-derived stem cells in the upper fraction of centrifuged lipoaspirates but the maximal concentration of adipose fraction after membrane-based tissue filtration. In conclusion, both studies seem to suggest superiority of manual aspiration and centrifugation and/or washing procedures-in line with both the British and German clinical guidelines 57,58 -but longer follow-up for the former, and affirmation in clinical practice for the latter study is necessary to make conclusive statements. As was stated in the recent systematic review of Shim et al., 59 the same can be said for harvest location, because multiple studies have shown a great varying degree in adipocyte number, volume, and morphology and also adipocyte-derived stem cells depending on where the fat is harvested.
Complications after dermal fillers are usually divided into early and late events and again into minor and major. 8 One of the advantages of AFT over other facial fillers in both early and late events is the absence of hypersensitivity reactions and granuloma formation, respectively. Furthermore, when comparing AFT with the use of hyaluronic acid (HA) fillers, major complications such as necrosis and blindness-which have both been described after HA injection 60-63 -were not reported. The most reported complication after AFT for facial rejuvenationhematoma/ecchymosis-was reported in 5% (95% CI: 2.0-15.0) of the total cohort, which is in line with that reported in studies using other dermal fillers. 64 Late onset complications such as fat necrosis (2.0%, n = 629) have been reported but are among the other complications 10,11 minimal. As stated before, the long-term volume retention is crucial in defining AFT as a biocompatible permanent filler in general and in verifying its superiority over other fillers. Three studies 40, 45, 51 reported an overall volume retention ranging from 40% to 68% over a follow-up of 6 to 12 months without specifying the injected locations. The remaining studies 36, 38 while specifying the locations (nasolabial/marionette fold and cheek/malar, respectively) reported much lower volume retentions, ranging from 13% to 19% over a follow-up of 12 months indicating the importance of the location in regard to the long-term retention of the reinjected fat. However, because of the great heterogeneity among studies-especially when it comes to the different injected facial zones-no definitive conclusion could be made with regard to overall volume retention after AFT for facial rejuvenation. Supplements were used in 2 studies that reported on volume retention 36, 51 ; however the injected facial zones, the method of measuring volume retention, and the supplements used (PrP/PrF vs SVF) all varied, so no beneficial effect could be reported. Therefore, the aim of further studies should be toward facial location-specific volumetric assessment using objectifiable tools like 3D imaging (such as the VECTRA XT 3D imaging system), CT, or MRI.
The patient and surgeon satisfaction rates in the included studies were considered acceptable and in line with other publications and a recently published study on quality of life after minimally invasive facial cosmetic procedures. 65 However, only standard visual analog scales, and also Likert scales, were used without the inclusion of validated questionnaires like the FACE-Q. 66 Also satisfaction scores per facial zone are only reported in 1 study 35 on VAS, ranging from 6 in the lips to 9 in the eyelids and malar region. Therefore, further studies should focus on incorporating the FACE-Q into the study design and report per facial zone. Overview of the auxiliary method, the method of measuring volume retention, the mean total injected volume, the volume gain, and the percentage of gain relative to the injected volume. NLF, nasolabial fold; NR, not reported; NS, not specified; PRF, platelet-rich fibrin; PRP, platelet-rich plasma.
Limitations
This systematic review has several limitations. Only low-level evidence studies (OCEBM III) and mainly retrospective studies without a control group were found. The 3 studies that used a comparative study design failed to report on some important aspects like allocation concealment and blinding, as is illustrated in Figure 2 . The use of validated measurement tools to assess patient-reported outcomes is lacking, and objectifiable data on volume retention are generally absent. Heterogeneity between studies in reported outcomes and nomenclature regarding specific facial zones and complications makes it difficult to draw conclusions. This was partly resolved by combining similar terms under 1 common nominator (eg, bruising and ecchymosis), but this may have introduced some bias. More important is the fact that several studies neglected to specify the complications and only sufficed with the annotation that there were none. These studies 67, 68 were therefore excluded, and this adds further to a possible reporting bias. Finally, the very definition of a complication of AFT in facial rejuvenation is a complicated matter and a clear consensus whether, for example, postoperative pain qualifies as a complication or part of the normal postoperative course is still lacking. A strong example thereof is the 38% rate of hematoma in the study of Zeltzer et al., 47 which deviates significantly from the reported rate in the rest of the studies, and while the authors tried to correct this by using a random-effect model, the reader should be cautious in interpreting these results. Therefore, on a methodological basis, the focus for further studies should be, first, to define complications and, second, to adhere to this definition when reporting on complications. In reporting on patient/surgeon satisfaction, the authors took certain liberties in translating Likert scales to dichotomous (satisfied vs dissatisfied) data by categorizing "moderately satisfied"-in a 3-point Likert scale-under "satisfied," because the patients might answered differently when presented with an actual dichotomous question. This should be kept in mind when interpreting these results.
The aim of this study was to complement the broad database of descriptive reviews and expert opinions on the subject of AFT for facial rejuvenation with the addition of a more comprehensive, systematically reviewed overview of the recent literature, including meta-analysis of complications and satisfaction. The authors believe this systematic review accomplishes that by the inclusion of structured tables on im- portant outcomes and also the exclusion of case series and case reports and studies with insufficient follow-up periods.
CONCLUSIONS
This systematic review provides an updated overview of the important outcomes of AFT for facial rejuvenation. Although the evidence in this review is still limited and plagued by the same heterogeneity that is often found in reporting on AFT for other indications, still, this technique is regarded as a promising method in facial rejuvenation. Although AFT has a number of obvious advantages over other dermal fillers in terms of biocompatibility, such as the absence of hypersensitivity reactions and the risks of granuloma formation, other complications such as fat necrosis have to be taken into account. Furthermore, the great variation in reported volume retentions in this systematic review suggests further studies are needed to clarify the facial-unit-specific, long-term preservation of the achieved volume before AFT can rightfully be called a true permanent filler. However, in achieving these goals, proper research should evaluate whether AFT is the superior biocompatible next-generation facial filler.
